OncLive Staff

Gedatolisib plus fulvestrant, with or without palbociclib, has been added to the NCCN guidelines for select patients with previously treated breast cancer.

First-line tislelizumab plus gemcitabine produced durable responses in platinum-ineligible locally advanced or metastatic urothelial carcinoma.

Obinutuzumab plus zanubrutinib produced high complete response rates with manageable toxicity in older patients with previously untreated mantle cell lymphoma.

Darlifarnib plus cabozantinib showed durable responses and manageable safety in cabozantinib-naive advanced clear cell RCC.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Shorter treatments of venetoclax plus azacitidine did not meet similarity criteria for longer treatments in the OPTI-AML trial.

A supplemental new drug application for selinexor plus ruxolitinib for myelofibrosis in August 2026 under the accelerated approval pathway.

Selinexor maintenance failed to significantly improve PFS vs placebo in TP53 wild-type advanced or recurrent endometrial cancer in the phase 3 XPORT-EC-042 trial.

A post-hoc analysis of LITESPARK-005 found that higher baseline and improved on-treatment QOL scores tracked with lower risk of disease progression and death.

Dato-DXd was approved in the European Union as monotherapy for patients with first-line metastatic TNBC who are not candidates for immunotherapy.

The FDA has granted priority review to subcutaneous amivantamab and hyaluronidase-lpuj for adults with recurrent or metastatic head and neck cancer.

The FDA has granted orphan drug designation to enzomenib for acute lymphoblastic leukemia.

Leukocyte interleukin injection improved OS in patients with oral cancer expressing low tumor PD-L1 levels.

FDA has granted RMAT and fast track designations to cema-cel as a frontline consolidation in large B-cell lymphoma.

Phase 3 data support EGFR and ALK inhibitors as adjuvant standards of care in resectable NSCLC.

Five-year outcomes from neoadjuvant, adjuvant, and perioperative immunotherapy trials in resectable NSCLC clarify which patients benefit most.

Ris-rez improved PFS vs chemotherapy in the ARTEMIS-011 trial for relapsed/refractory osteosarcoma.

Phase 3 BOND-003 cohort C findings showed a 75.5% CR rate and durable bladder preservation in high-risk, BCG-unresponsive NMIBC.

The FDA approved SimpleScreen CRC as a screening option for colorectal cancer in adults 45 years of age and older at average risk for the disease.

Sonesitatug vedotin improved overall survival in pretreated CLDN18.2-positive advanced gastric/GEJ cancers in the phase 3 CLARITY-Gastric01 trial.

Safusidenib produced a 51.9% confirmed ORR and a 79.1% 36-month PFS rate in chemotherapy- and radiotherapy-naive grade 2 IDH1-mutant glioma.

Faculty convened at an OncLive Scientific Interchange and Workshop to discuss individualizing ARPI-based therapy in advanced prostate cancer.

The top 5 OncLive TV videos of the week cover insights in pancreatic cancer, non–small cell lung cancer, the cost and value of immunotherapy, and bladder cancer.

The FDA accepted an NDA for daraxonrasib in metastatic pancreatic cancer, approved zidesamtinib in pretreated ROS1-positive NSCLC, and more.

The CHMP recommended EU approval of T-DXd plus pertuzumab as first-line therapy for HER2-positive metastatic breast cancer,

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The CHMP has recommended the approval of sacituzumab govitecan/pembrolizumab for treatment-naive, PD-L1-positive metastatic TNBC in the European Union.

Overall survival was the sole US primary end point of the phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab and was not met.

Teclistamab plus talquetamab met the primary PFS end point and improved overall survival in relapsed/refractory multiple myeloma in MonumenTAL-6.

The FDA has granted priority review to a supplemental application for talazoparib plus enzalutamide in HRR-altered mCSPC.